Treatment of relapsed Hodgkin's disease: Strategies and prognostic factors

Annals of Oncology

Volumn 9, Issue SUPPL. 5, 1998, Pages

  Canellos, G P ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Hodgkin's disease; Prognostic factors; Relapse; Salvage chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; ARABINOSIDE; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LOMUSTINE; MITOGUAZONE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; SARCOLYSIN; VINBLASTINE; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; HODGKIN DISEASE; HUMAN; META ANALYSIS; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

EID: 0032447913     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/9.suppl_5.S91     Document Type: Conference Paper

References (5)

1. Rosenberg SA. The treatment of Hodgkin's disease. Ann Oncol 1994; 5 (Suppl 2): S17-21.
2. Henry-Amar M, Joly F. Late complications after Hodgkin's disease. Ann Oncol 1996; 7 (Suppl 4): S115-26.
3. Cosset JM, Fermé C, Noordijk EM et al. Combined modality treatment for poor prognosis stages I and II Hodgkin's disease. Semin Radiat Oncol 1996; 6: 185-95.
4. Lister TA, Crowther D, Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswold meeting. J Clin Oncol 1989; 7: 1630-6.
5. Jochelson M, Mauch P, Balikian J et al. The significance of the residual mediastinal mass in treated Hodgkin's disease. J Clin Oncol 1985; 3: 637-40.